| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
4,717 |
3,993 |
$240K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
2,025 |
1,840 |
$167K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
4,639 |
4,120 |
$96K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
1,865 |
1,584 |
$66K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
7,362 |
3,312 |
$61K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
3,720 |
3,238 |
$32K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
518 |
479 |
$31K |
| 87428 |
|
593 |
540 |
$25K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
2,239 |
2,040 |
$24K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
2,797 |
2,306 |
$21K |
| 71046 |
Radiologic examination, chest; 2 views |
606 |
535 |
$9K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
506 |
404 |
$9K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
333 |
260 |
$8K |
| 87807 |
|
868 |
804 |
$8K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
265 |
204 |
$4K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
417 |
376 |
$3K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
56 |
53 |
$3K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
33 |
30 |
$2K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
847 |
735 |
$1K |
| 81002 |
|
577 |
503 |
$1K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
1,403 |
1,231 |
$513.62 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
173 |
142 |
$232.31 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
26 |
13 |
$170.00 |
| 81025 |
|
58 |
50 |
$95.20 |
| A7003 |
Administration set, with small volume nonfiltered pneumatic nebulizer, disposable |
327 |
310 |
$28.18 |
| J7644 |
Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram |
397 |
356 |
$0.52 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
415 |
374 |
$0.13 |
| 1125F |
|
70 |
56 |
$0.00 |
| 3008F |
|
5,120 |
4,284 |
$0.00 |
| 1170F |
|
267 |
196 |
$0.00 |
| G8419 |
Bmi documented outside normal parameters, no follow-up plan documented, no reason given |
40 |
31 |
$0.00 |
| 1159F |
|
33 |
25 |
$0.00 |
| 1494F |
|
39 |
28 |
$0.00 |
| 1160F |
|
33 |
25 |
$0.00 |